Myostatin inhibits proliferation and insulin-stimulated glucose uptake in mouse liver cells

Biochemistry and Cell Biology

Volumn 92, Issue 3, 2014, Pages 226-234

  Watts, Rani ^a   Ghozlan, Mostafa ^a   Hughey, Curtis C ^a   Johnsen, Virginia L ^a   Shearer, Jane ^a   Hittel, Dustin S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cell cycle; Glucose metabolism; Hepatogenesis; Malat1 siRNA; Myostatin

Indexed keywords

AMINO ACIDS; CELL PROLIFERATION; ENZYMES; GLUCOSE; INSULIN; MAMMALS; MUSCLE; PHOSPHORYLATION; POLYMERASE CHAIN REACTION;

CELL CYCLE; GLUCOSE METABOLISM; HEPATOGENESIS; MALAT1 SIRNA; MYOSTATIN;

CELLS;

CYCLIN DEPENDENT KINASE; CYCLINE; GLUCOSE; INSULIN; LONG UNTRANSLATED RNA; MARCKS PROTEIN; MEMBRANE PROTEIN; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MYOSTATIN; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MALAT1 LONG NON-CODING RNA, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; LIVER CELL CULTURE; LIVER REGENERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SKELETAL MUSCLE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIVER; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GLUCOSE; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MYOSTATIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, LONG NONCODING; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84901982944     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0004     Document Type: Article

References (49)

1. Akita Y. Sumino Y. Mori K. Nomura T. Sato F. Mimata H. 2013. Myostatin inhibits proliferation of human urethral rhabdosphincter satellite cells. Int. J. Urol. 20 (5): 522-529. 10.1111/j.1442-2042.2012.03186.x. 23050675.
2. Allen D.L. Hittel D.S. McPherron A.C. 2011. Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med. Sci. Sports Exerc. 43 (10): 1828-1835. 10.1249/MSS.0b013e3182178bb4. 21364474.
3. Antony N. Bass J.J. McMahon C.D. Mitchell M.D. 2007. Myostatin regulates glucose uptake in BeWo cells. Am. J. Physiol. Endocrinol. Metab. 293 (5): E1296-E1302. 10.1152/ajpendo.00331.2007. 17711997.
4. Bonala S. Lokireddy S. McFarlane C. Patnam S. Sharma M. Kambadur R. 2014. Myostatin induces insulin resistance via Cblb-mediated degradation of IRS1 in response to high calorie diet intake. J. Biol. Chem. 289: 7654-7670. 10.1074/jbc.M113.529925. 24451368.
5. Bonomi L. Brown M. Ungerleider N. Muse M. Matzuk M.M. Schneyer A. 2012. Activin B regulates islet composition and islet mass but not whole body glucose homeostasis or insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 303 (5): E587-E596. 10.1152/ajpendo.00177.2012. 22739106.
6. Calle R. Ganesan S. Smallwood J.I. Rasmussen H. 1992. Glucose-induced phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in isolated rat pancreatic islets. J. Biol. Chem. 267 (26): 18723-18727. 1527003.
7. Chappell D.S. Patel N.A. Jiang K. Li P. Watson J.E. Byers D.M. Cooper D.R. 2009. Functional involvement of protein kinase C-betaII and its substrate, myristoylated alanine-rich C-kinase substrate (MARCKS), in insulin-stimulated glucose transport in L6 rat skeletal muscle cells. Diabetologia, 52 (5): 901-911. 10.1007/s00125-009-1298-7. 19252893.
8. Chauhan A. Lorenzen S. Herzel H. Bernard S. 2011. Regulation of mammalian cell cycle progression in the regenerating liver. J. Theor. Biol. 283 (1): 103-112. 10.1016/j.jtbi.2011.05.026. 21635899.
9. Chen, C.H., Thai, P., Yoneda, K., Adler, K.B., Yang, P.C., and Wu, R. 2013. A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene. In press. 10.1038/onc.2013.336. 23955080.
10. Chen W. Woodruff T.K. Mayo K.E. 2000. Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology, 141 (3): 1263-1272. 10.1210/endo.141.3.7361. 10698204. (Pubitemid 32260471)
11. Chen Y. Ye J. Cao L. Zhang Y. Xia W. Zhu D. 2010. Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. Int. J. Biochem. Cell Biol. 42 (12): 2072-2081. 10.1016/j.biocel.2010.09.017. 20887798.
12. Dasarathy S. 2012. Consilience in sarcopenia of cirrhosis. J. Cachexia Sarcopenia Muscle, 3 (4): 225-237. 10.1007/s13539-012-0069-3. 22648736.
13. Dasarathy S. McCullough A.J. Muc S. Schneyer A. Bennett C.D. Dodig M. Kalhan S.C. 2011. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J. Hepatol. 54 (5): 915-921. 10.1016/j.jhep.2010.08.032. 21145817.
14. Feldman B.J. Streeper R.S. Farese R.V. Jr. Yamamoto K.R. 2006. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc. Natl. Acad. Sci. U.S.A. 103 (42): 15675-15680. 10.1073/pnas.0607501103. 17030820. (Pubitemid 44625651)
15. Garcia P.S. Cabbabe A. Kambadur R. Nicholas G. Csete M. 2010. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth. Analg. 111 (3): 707-709. 10.1213/ANE.0b013e3181eac1c9. 20686014.
16. Guo W. Wong S. Bhasin S. 2013. AAV-Mediated Administration of Myostatin Pro-Peptide Mutant in Adult Ldlr Null Mice Reduces Diet-Induced Hepatosteatosis and Arteriosclerosis. PloS One 8 (8): e71017. 10.1371/journal.pone.0071017. 23936482.
17. Han Y. Liu Y. Nie L. Gui Y. Cai Z. 2013. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder. Urology, 81 (1): 209 e201-e207. 10.1016/j.urology.2012.08.044. 23153939.
18. Hirota K. Fukamizu A. 2010. Transcriptional regulation of energy metabolism in the liver. J. Recept. Signal Transduct. Res. 30 (6): 403-409. 10.3109/10799893.2010.509730. 20735177.
19. Hittel D.S. Berggren J.R. Shearer J. Boyle K. Houmard J.A. 2009. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes, 58 (1): 30-38. 10.2337/db08-0943. 18835929.
20. Hittel D.S. Axelson M. Sarna N. Shearer J. Huffman K.M. Kraus W.E. 2010. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. 42 (11): 2023-2029. 10.1249/MSS. 0b013e3181e0b9a8. 20386333.
21. Jiao J. Yuan T. Zhou Y. Xie W. Zhao Y. Zhao J. et al 2011. Analysis of myostatin and its related factors in various porcine tissues. J. Anim. Sci. 89 (10): 3099-3106. 10.2527/jas.2010-3827. 21571901.
22. Joulia D. Bernardi H. Garandel V. Rabenoelina F. Vernus B. Cabello G. 2003. Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp. Cell Res. 286 (2): 263-275. 10.1016/S0014-4827(03)00074-0. 12749855. (Pubitemid 36566439)
23. Lang C.H. Frost R.A. Svanberg E. Vary T.C. 2004. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am. J. Physiol. Endocrinol. Metab. 286 (6): E916-E926. 10.1152/ajpendo.00554.2003. 14749210.
24. Lee T.V. Ding T. Chen Z. Rajendran V. Scherr H. Lackey M. et al 2008. The E1 ubiquitin-activating enzyme Uba1 in Drosophila controls apoptosis autonomously and tissue growth non-autonomously. Development, 135 (1): 43-52. 10.1242/dev.011288. 18045837. (Pubitemid 351201480)
25. Leevy C.B. 1998. Abnormalities of liver regeneration: a review. Dig. Dis. 16 (2): 88-98. 10.1159/000016852. 9571374. (Pubitemid 128530657)
26. Lin R. Roychowdhury-Saha M. Black C. Watt A.T. Marcusson E.G. Freier S.M. Edgington T.S. 2011. Control of RNA processing by a large non-coding RNA over-expressed in carcinomas. FEBS Lett. 585 (4): 671-676. 10.1016/j.febslet. 2011.01.030. 21266177.
27. Luo J.H. Ren B. Keryanov S. Tseng G.C. Rao U.N. Monga S.P. et al 2006. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 44 (4): 1012-1024. 10.1002/hep.21328. 17006932. (Pubitemid 46489565)
28. McCroskery S. Thomas M. Maxwell L. Sharma M. Kambadur R. 2003. Myostatin negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162 (6): 1135-1147. 10.1083/jcb.200207056. 12963705. (Pubitemid 37174195)
29. McCroskery S. Thomas M. Platt L. Hennebry A. Nishimura T. McLeay L. et al 2005. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J. Cell Sci. 118 (15): 3531-3541. 10.1242/jcs.02482. 16079293. (Pubitemid 41246106)
30. McFarland D.C. Velleman S.G. Pesall J.E. Liu C. 2006. Effect of myostatin on turkey myogenic satellite cells and embryonic myoblasts. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 144 (4): 501-508. 10.1016/j.cbpa.2006.04.020. 16750409. (Pubitemid 43994512)
31. McPherron A.C. Lee S.J. 2002. Suppression of body fat accumulation in myostatin-deficient mice. J. Clin. Invest. 109 (5): 595-601. 10.1172/JCI13562. 11877467. (Pubitemid 34204838)
32. Mirza, Z., Kamal, M.A., Abuzenadah, A.M., Al-Qahtani, M.H., and Karim, S. 2013. Establishing Genomic/Transcriptomic Links between Alzheimers Disease and Type II Diabetes Mellitus by Meta-Analysis Approach. CNS Neurol. Disord. Drug Targets. 24059308.
33. Mitchell M.D. Osepchook C.C. Leung K.C. McMahon C.D. Bass J.J. 2006. Myostatin is a human placental product that regulates glucose uptake. J. Clin. Endocrinol. Metab. 91 (4): 1434-1437. 10.1210/jc.2005-2361. 16464946.
34. ORahilly S. 2009. Human genetics illuminates the paths to metabolic disease. Nature, 462 (7271): 307-314. 10.1038/nature08532. 19924209.
35. Pedersen B.K. Febbraio M.A. 2012. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8 (8): 457-465. 10.1038/nrendo.2012.49. 22473333.
36. Pedersen L. Hojman P. 2012. Muscle-to-organ cross talk mediated by myokines. Adipocyte, 1 (3): 164-167. 10.4161/adip.20344. 23700527.
37. Rios R. Carneiro I. Arce V.M. Devesa J. 2001. Myostatin regulates cell survival during C2C12 myogenesis. Biochem. Biophys. Res. Commun. 280 (2): 561-566. 10.1006/bbrc.2000.4159. 11162556. (Pubitemid 32912828)
38. Rios R. Fernandez-Nocelos S. Carneiro I. Arce V.M. Devesa J. 2004. Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo. Endocrinology, 145 (6): 2795-2803. 10.1210/en.2003-1166. 14976141. (Pubitemid 38686229)
39. Schmidt L.H. Spieker T. Koschmieder S. Schaffers S. Humberg J. Jungen D. et al 2011. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J. Thorac. Oncol. 6 (12): 1984-1992. 10.1097/JTO.0b013e3182307eac. 22088988.
40. Siriett V. Salerno M.S. Berry C. Nicholas G. Bower R. Kambadur R. Sharma M. 2007. Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol. Ther. 15 (8): 1463-1470. 10.1038/sj.mt.6300182. 17551508. (Pubitemid 47099303)
41. Taylor W.E. Bhasin S. Artaza J. Byhower F. Azam M. Willard D.H. Jr. et al 2001. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am. J. Physiol. Endocrinol. Metab. 280 (2): E221-E228. 11158924.
42. Thomas M. Langley B. Berry C. Sharma M. Kirk S. Bass J. Kambadur R. 2000. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J. Biol. Chem. 275 (51): 40235-40243. 10.1074/jbc.M004356200. 10976104. (Pubitemid 32064654)
43. Wang F. Liao Y. Li X. Ren C. Cheng C. Ren Y. 2012. Increased circulating myostatin in patients with type 2 diabetes mellitus. J. Huazhong Univ. Sci. Technol. Med. Sci. 32 (4): 534-539. 10.1007/s11596-012-0092-9. 22886966.
44. Watts R. Johnsen V.L. Shearer J. Hittel D.S. 2013. Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. Am. J. Physiol. Cell Physiol. 304 (10): C995-C1001. 10.1152/ajpcell.00392.2012. 23485710.
45. Wilkes J.J. Lloyd D.J. Gekakis N. 2009. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes, 58 (5): 1133-1143. 10.2337/db08-0245. 19208906.
46. Yang W. Zhang Y. Li Y. Wu Z. Zhu D. 2007. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J. Biol. Chem. 282 (6): 3799-3808. 10.1074/jbc.M610185200. 17130121. (Pubitemid 47084479)
47. Zhang C. McFarlane C. Lokireddy S. Bonala S. Ge X. Masuda S. et al 2011. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia, 54 (6): 1491-1501. 10.1007/s00125-011-2079-7. 21347623.
48. Zhang C. McFarlane C. Lokireddy S. Masuda S. Ge X. Gluckman P.D. et al 2012. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia, 55 (1): 183-193. 10.1007/s00125-011-2304-4. 21927895.
49. Zimmers T.A. Davies M.V. Koniaris L.G. Haynes P. Esquela A.F. Tomkinson K.N. et al 2002. Induction of cachexia in mice by systemically administered myostatin. Science, 296 (5572): 1486-1488. 10.1126/science.1069525. 12029139. (Pubitemid 34553097)